Reuters logo
BRIEF-Teva sees 2017 adjusted profit $4.90 to $5.30/shr
February 13, 2017 / 12:03 PM / 10 months ago

BRIEF-Teva sees 2017 adjusted profit $4.90 to $5.30/shr

Feb 13 (Reuters) - Teva Pharmaceutical Industries Ltd

* Teva reports full year and fourth quarter 2016 financial results

* Sees fy 2017 non-gaap earnings per share $4.90 to $5.30

* Sees fy 2017 revenue $23.8 billion to $24.5 billion

* Q4 revenue rose 33 percent to $6.5 billion

* Teva pharmaceutical industries ltd - reaffirms its 2017 full year non-gaap guidance

* Teva pharmaceutical industries ltd - teva reaffirms its 2017 full year non-gaap guidance

* Teva pharmaceutical industries ltd - qtrly non-gaap eps $1.38

* Teva pharmaceutical industries ltd- generic medicines revenues in q4 of 2016 were $3.7 billion, an increase of 44% compared to q4 of 2015

* Teva pharmaceutical industries ltd - qtrly gaap loss per share $1.10

* Teva pharmaceutical industries ltd says specialty medicines revenues in q4 of 2016 were $2.2 billion, up 4% compared to q4 of 2015

* Teva pharmaceutical industries ltd - qtrly global revenues of copaxone in u.s. And globally, were $1.0 billion, an increase of 6% compared to q4 of 2015 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below